Effective interventions for potentially modifiable late-onset dementia risk factors: a costs and cost-effectiveness modelling study by Mukadam, Naaheed et al.
www.thelancet.com/healthy-longevity   Vol 1   October 2020 e13
Articles
Lancet Healthy Longev 2020; 
1: e13–20
See Comment page e2
Division of Psychiatry, 
University College London, 
London, UK (N Mukadam PhD, 
S G Costafreda PhD, 
M Tutton MSc, 
Prof G Livingston MD); Camden 
and Islington NHS Foundation 
Trust, London, UK (N Mukadam, 
S G Costafreda, 
Prof G Livingston); Care Policy 
and Evaluation Centre, London 
School of Economics and 
Political Science, London, UK 
(R Anderson MA, 
Prof M Knapp PhD, 
R Wittenberg MSc, 
M Karagiannidou MSc); and 
Public Health England, London, 
UK (C Alessi MBBS)
Correspondence to:  
Dr Naaheed Mukadam, Division 
of Psychiatry, University College 
London, London W1T 7NF, UK 
n.mukadam@ucl.ac.uk
Effective interventions for potentially modifiable risk factors 
for late-onset dementia: a costs and cost-effectiveness 
modelling study
Naaheed Mukadam, Robert Anderson, Martin Knapp, Raphael Wittenberg, Maria Karagiannidou, Sergi G Costafreda, Madison Tutton , 
Charles Alessi, Gill Livingston
Summary
Background The potential economic value of interventions to prevent late-onset dementia is unknown. We modelled 
this for potentially modifiable risk factors for dementia.
Methods For this modelling study, we searched PubMed and Web of Science from inception to March 12, 2020, and 
included interventions that: successfully targeted any of nine prespecified potentially modifiable risk factors 
(hypertension, diabetes, hearing loss, obesity, physical inactivity, social isolation, depression, cigarette smoking, and 
less childhood education); had robust evidence that the intervention improved risk or risk behaviour; and are feasible 
to enact in an adult population. We established when in the life course each intervention would be delivered. We 
calculated dementia incidence reduction from annual incidence of dementia in people with each risk factor, and 
population attributable fraction for each risk, corrected for risk factor clustering, and how effectively the intervention 
controls the risk factor. We calculated the discounted value of lifetime health gain and effect on cost (including NHS, 
social care and carer costs) per person eligible for treatment. We estimated annual total expenditure on the fully 
operational intervention programme in England.
Findings We found effective interventions for hypertension, smoking cessation, diabetes prevention, and hearing loss. 
Treatments for stopping smoking and provision of hearing aids reduced cost. Treatment of hypertension was cost-
effective by reference to standard UK thresholds. The three interventions when fully implemented would save 
£1·863 billion annually in England, reduce dementia prevalence by 8·5%, and produce quality-adjusted life-year 
gains. The intervention for diabetes was unlikely to be cost-effective in terms of effect on dementia alone.
Interpretation There is a strong case for implementing the three effective interventions on grounds of cost-
effectiveness and quality-of-life gains, as well as for improvements in general health. The interventions have the 
potential to remain cost-saving or cost-effective even with variations in dementia incidence and costs and effectiveness 
of interventions.
Funding Economic and Social Research Council.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licence.
Introduction
An estimated 47 million people live with dementia 
worldwide, and this is predicted to increase to 131 million 
by 2050.1 People are living longer than in previous years,2 
particularly in low-income and middle-income 
countries.1 The annual global cost of dementia is already 
estimated to be US$1 trillion,3 showing how dementia 
affects indivi duals, families, and economies.
The incidence of age-specific dementia has decreased 
in some countries over the past two decades, suggesting 
that the risk of dementia is modifiable. We calculated a 
combined population-attributable fraction (PAF) for 
nine potentially modifiable risks for all-cause dementia 
from National Institute for Health and Care Excellence 
and National Institutes of Health guidelines (less 
childhood education, hearing loss, hypertension, 
obesity, smoking, physical inactivity, depression, 
diabetes, and social isolation), finding that up to 35% of 
all-cause late-onset dementia worldwide might be 
preventable.4
There has been little work on feasibility, effectiveness, 
or cost-effectiveness of interventions to prevent 
dementia. Earlier work has not accounted for clustering 
of risks in individuals—for example, people with obesity 
more often have hypertension and diabetes than do 
members of the general population. The best supported 
inter vention is treating cardiovascular risks to prevent 
cognitive decline. One USA model estimated health-
care savings of US$110 billion from a 10% reduction in 
four risk factors (body-mass index [BMI] ≥25 kg/m²; 
diabetes; hypertension; cardiovascular diseases, 
including stroke and heart diseases), although this 
model did not specify or cost the intervention.5 A 
Spanish model of (uncosted) primary prevention 
interventions resulting in 20% improvements in 
obesity, hypercholesterolaemia, physical activity, and 
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hypertension concluded that dementia prevalence could 
decrease by 9%, saving €5 billion annually by 2050.6 
Similarly, a model of the effects of increasing physical 
activity on dementia among middle-aged people (aged 
45–64 years) in England concluded that it would be cost-
saving in addition to increasing life-expectancy.7 Only 
one study costed interventions: a health-promotion 
programme to lower serum cholesterol and provide 
pharmacological treatment of hypertension, hyper-
cholesterolaemia, and diabetes in a Swedish and 
Finnish population;8 the intervention group had lower 
costs and gained 0·0511 quality-adjusted life-years 
(QALYs) over 20 years.9
We systematically identified interventions of proven 
effectiveness in reducing individual risk or risk 
behaviours, and which were feasible in an adult 
population. We then modelled, for the first time to our 
knowledge, potential costs and cost-effectiveness of late-
onset (age 65 years and older) all-cause dementia 
prevention through employing such interventions. We 
assume some people with each risk factor will already be 
receiving treatment, estimate how many are not currently 
receiving treatment, and calculate costs and benefits for 
the intervention. Focusing on England, we calculate 
potential costs and savings, accounting for risk clustering 
in individuals, and associated effects on QALYs.
Research in context
Evidence before this study
We searched PubMed and Web of Science, from inception to 
March 12, 2020, with no language restrictions, for effective 
interventions targeting each of the nine specified potentially 
modifiable risk factors. We used search terms for each risk 
factor, combined with terms for interventions or trials, for 
example, “hypertension”, “intervention” OR “trial” OR 
“treatment”. We then searched PubMed from inception to 
March 12, 2020, for studies investigating the cost-
effectiveness of dementia prevention using these 
interventions. We used search terms “dementia” AND 
“prevent*” AND “economic” OR “cost” with no restrictions on 
language or date of publication. We then hand-searched 
retrieved papers for relevant references. We found one 
systematic review of interventions targeting cardiovascular 
risk factors (hypertension, dyslipidaemia, 
hyperhomocysteinaemia, obesity, or diabetes mellitus) and the 
effect on cognitive decline or dementia, but this did not 
include a cost-effectiveness analysis. We found four studies 
assessing the economic impact of tackling a range of 
potentially modifiable risk factors on dementia prevalence. 
Three of these did not account for clustering of risk factors—
for example, an individual might have hypertension and 
diabetes and be physically inactive; nor did they include costs 
of the interventions. However, they concluded that 
considerable savings would be associated with reducing risk 
factors because of the effect on dementia onset and 
prevalence. A fourth study investigated the effect of a health 
promotion programme combined with medication for 
cardiovascular risk factors (hypertension, 
hypercholesterolaemia, and diabetes) and found that the 
intervention group had lower costs and a small gain in quality-
adjusted life-years (QALYs) over a 20-year period. This study 
assessed the effect of reducing cardiovascular risk factors and 
did not account for clustering of risk in an individual.
We have previously published estimates of population 
attributable fractions for nine dementia risk factors identified 
from National Institute for Health and Care Excellence and 
National Institutes of Health guidelines. They were calculated 
on the basis of worldwide prevalence estimates and adjusted 
for clustering of risk factors in the individual. We found that 
eliminating these nine factors potentially meant that up to 
35% of dementia is preventable worldwide. No studies have 
considered the potential for preventing dementia considering 
all these risk factors or examined the potential economic 
consequences.
Added value of this study
We used previously established relative risks for the 
nine prespecified risk factors associated with dementia 
(hypertension, diabetes, hearing loss, obesity, physical inactivity, 
social isolation, depression, cigarette smoking, and fewer years 
of childhood education) and searched systematically up to 
March 12, 2020, for effective interventions that were feasible in 
the adult population. We found interventions for mid-life 
hypertension and hearing loss, and diabetes and smoking in later 
life. We then modelled cost-effectiveness for these, considering 
the effectiveness of the treatments and the clustering of risk 
factors in individuals. We calculated that stopping smoking and 
provision of hearing aid led to both cost saving and QALY gains. 
Treating hypertension proved cost-effective according to 
standard thresholds at a cost of £9550 per QALY. Preventing 
diabetes was unlikely to be cost-effective on the basis of its 
effects on dementia alone. This study provides robust evidence 
regarding which risk factors for dementia are worth targeting. 
We also show the benefits of dementia prevention using well 
established standards of cost-effectiveness while considering 
clustering of risk factors in an individual.
Implications of all the available evidence
Treating hypertension, stopping smoking, and providing hearing 
aids to those who need them would eventually reduce the 
prevalence of dementia by 8·5% and save England £1·863 billion 
per year (at 2012–13 prices) in health care, social care, and unpaid 
care costs. These interventions are worth implementing for their 
effect on dementia alone. If dementia is delayed until very old 
age, rather than prevented, a compression of morbidity would be 
anticipated with people living longer without illness and a 
shorter time with multiple illnesses. These calculations are likely 
to be generalisable and relevant to other countries considering 
implementing dementia prevention strategies.
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Methods
Inclusion of interventions and approach to analysis
For this modelling study, we searched PubMed and Web 
of Science, from inception to March 12, 2020, with no 
language restrictions, for interventions targeting each of 
the nine specified dementia risk factors (less childhood 
education, hearing loss, hypertension, obesity, smoking, 
physical inactivity, depression, diabetes, and social 
isolation). We categorised time of treatment as early 
(younger than age 45 years), mid-life (age 45–64 years), or 
later life (65 years and older) to maintain consistency 
with previous evidence.10 We used search terms for each 
risk factor, combined with terms for interventions or 
trials—for example, “hypertension”, “intervention” OR 
“trial” OR “treatment”. We then searched PubMed from 
inception to March 12, 2020, for studies investigating the 
cost-effectiveness of prevention of dementia using these 
interventions. We used search terms “dementia” AND 
“prevent*” AND “economic” OR “cost” with no 
restrictions on language or date of publication. We then 
hand-searched retrieved papers for relevant references. 
One reviewer (NM) checked the articles to ensure that 
the described interventions met the inclusion criteria, 
which were robust evidence the intervention reduces or 
prevents risk or risk behaviour; and are feasible in an 
adult population.
There is consistent evidence for the effect of each risk 
factor on an individual’s subsequent risk of dementia. 
Our assumption was that treating or eliminating a risk 
factor would reduce a person’s risk of developing 
dementia to that of someone without the risk factor. 
Using published figures on dementia incidence and 
frequency of risk factors, we modelled the effects of 
treatments on the subsequent risk of dementia. We did 
not include case-finding for risk factors as our focus is the 
cost-effectiveness of intervention when provided to 
people who have already been identified as at risk. We 
costed interventions, modelled dementia incidence in 
inter vention and control groups, calculated costs and 
QALYs for those with and without dementia, and assumed 
transitions between different dementia severities and 
death. We used all-cause mortality by age and dementia 
severity to calculate survival to the next year.
Evidence on relative risks in England
We are considering the effect of each risk factor that 
predisposes to dementia. Our starting point is the PAF, 
the potential reduction in an illness in the whole 
population if the risk factor was eliminated. PAF is 
calculated by multiplying relative risk (RR) of each risk 
factor by the factor’s prevalence. A previous meta-
analyses report weighted PAF for each factor and 
adjusted for clustering (communality)4 to eliminate the 
effect of other factors. The RRs we used are therefore 
“partialled-out”; it is not assumed that individuals have 
only one risk factor. The formula for calculation of PAF 
is: 
in which r=adjusted RR, PAF=weighted population 
attributable fraction, and p=prevalence of risk factor. The 
required specific RR follows from the weighted PAF, 
using the equation
We identified nationally representative surveys4 to 
determine risk factor prevalence in England and to 
calculate PAF (see appendix p 1).
Economic analysis
Our modelling had a societal perspective incorporating 
the following: intervention cost; annual dementia 
incidence in people with the risk factor under 
consi deration; reduction in dementia incidence if risk 
factor is controlled to the extent that the identified 
intervention shows evidence of effectiveness; annual 
effect per person with dementia in old age in terms of 
QALY gain and excess health-care, social, and unpaid 
care costs; and incremental cost-effectiveness ratio.
We costed interventions using England-specific 
unit costs 2012–1311–13 for staff time and drugs14 
(appendix pp 2–3). We focused on incremental effects on 
dementia risk and prevalence, and did not consider 
effects on other conditions. We calculated cost-savings 
from reduced dementia prevalence from up-to-date cost-
of-illness figures.15 Details of annual costs per sector, by 
age group and dementia stage, and by quality of life and 
mortality are presented in the appendix (p 4). We 
established when in the life course each intervention 
would be delivered and discounted future dementia-
associated savings back to present value using annual 
discount rate of 3·5%, as recommended by the UK 
Treasury.16 We did one-way deterministic sensitivity 
analyses and probabilistic sensitivity analyses using 
Monte Carlo simulation for each intervention 
(appendix pp 9–11).
Data, modelling, and incidence of dementia
We used a Markov model previously developed for 
assessing cost-effectiveness for disease-modifying 
therapies in Alzheimer’s disease.17 Key inputs in this 
model are age-specific incidence of dementia in 
England,18 three stages of dementia (mild, moderate, and 
severe), transition rates between stages, excess mortality 
rates in moderate and severe stages, stage-specific costs 
(including health, social services, and unpaid care by 
family), and stage-specific QALY levels19 (appendix pp 2–7).
We used age-specific average NHS,18 social care, and 
unpaid care costs;20 these relate to the English population 
as a whole and are, in effect, weighted averages of costs 
for those with and without dementia (appendix pp 2–7). 
PAF=
p(r – 1)
1 + p(r – 1)
r=
p(1 – PAF) + PAF
p(1 – PAF)
See Online for appendix
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To derive costs for those with dementia, we used estimates 
of age-specific prevalence of dementia from the Cognitive 
Function and Ageing Study II21 and age-specific costs22 
accounting for changing stage distribution of dementia 
with age.
Data on dementia incidence relate to the whole 
population. To separate estimates for those with and 
without each risk factor, we used estimates of prevalence of 
risk factor (p) and RR of those with the factor compared 
with those without (r). Incidence in those with the risk 
factor is given by population incidence factored by the 
following equation:
The incidence in those without the risk factor is 
calculated with the following equation
Cost per QALY is calculated using the following 
equation:
For cases in which intervention dominates (ie, has better 
outcomes and lower costs), we quote the result in terms of 
per-person cost saving and QALY gain. Costs and benefits 
are those accruing over the individual’s lifetime, dis-
counted to the age at which therapy is initiated. For mid-
life interventions, we assume the intervention commences 
in mid-life but continues to end of life: both hearing aids17 
and antihypertensives23 continue to protect against 
dementia in later life.
Cost of the average patient’s treatment career accounts 
for death rate during the treatment period, using national 
average figures24 plus excess mortality attributable to later 
stages of dementia.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. RW and RA had full access to all the data in 
the study and had final responsibility for the decision to 
submit for publication.
Results
We identified four potential interventions with robust 
evidence of effectiveness in reducing dementia incidence.
The first potential intervention is for mid-life hyper-
tension. Several studies have shown that antihyper-
tensives treat hypertension effectively, with some 
showing effects on dementia.25 A reduction in the risk of 
dementia is observed even if blood pressure remains 
above hypertensive thresholds. Calculations of cost used 
three antihypertensives together if necessary, as 
recommended by NICE,26 assuming this would achieve 
sufficient hypertensive control to eliminate excess 
dementia risk of mid-life hypertension.
The second potential intervention is for smoking in 
later life. Smoking cessation reduces risk of dementia.27 
We identified any form of nicotine replacement therapy 
as the most effective intervention because it is a feasible 
intervention and commonly used. A meta-analysis 
showed that the RR of abstinence from smoking for any 
form of nicotine replacement therapy relative to control 
was 1·60, with effects largely independent of therapy 
duration, additional support intensity, or setting.28 We 
consider the use of nicotine gum for older people who 
smoke on the basis of the results of a meta-analysis,28 in 
which trial follow-up period was typically 6 months or 
12 months. We selected trials with a 12-month follow-up 
(with low support). There were ten trials with 
2751 participants, of whom 323 quit, but 40% of these 
resumed smoking, leading to a permanent quit rate of 
7%.29
The third potential intervention is for later-life type 2 
diabetes. We identified a lifestyle change intervention to 
prevent diabetes because to our knowledge there is no 
evidence that treating diabetes reduces the risk of 
developing dementia compared with untreated diabetes.30 
The Finnish Diabetes Prevention Study31 recruited middle-
aged, overweight participants with impaired glucose 
tolerance, following them up for 13 years. The treatment 
group had a consultation with their general practitioner 
(GP) yearly, had group physical exercise sessions and 
seven sessions with a nutritionist in year one, plus four 
each subsequent year in a continuing individualised 
lifestyle intervention. The annual incidence of diabetes 
was 4·5% in the intervention group and 7·2% in the 
control group.31
The fourth potential intervention is for mid-life hearing 
loss. We chose provision of a hearing aid as the 
intervention since increasing evidence from longitudinal 
studies shows that initiating hearing aid use slows 
memory decline, and continued use reduces dementia 
risk to that of people without hearing impairment.31 
People with hearing impairment who do not use hearing 
aids remain at an increased risk of dementia. We assume 
those with hearing aids avoid the excess risk associated 
with hearing loss.32
We were unable to model interventions for five risk 
factors for dementia. The first was education; education 
in England is compulsory through to age 18 years and so 
we could not increase childhood education to influence 
future dementia prevalence. The second was obesity; 
there was an absence of evidence for feasible 
interventions for the whole obese population that 
resulted in lowering BMI to below the obesity threshold. 
Incidence with risk factor =
r
(pr + 1 – p)
Incidence without 
       risk factor
Incidence with risk factor
r
=
Cost per QALY = 
Cost of intervention minus saving
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The third was depression; to our knowledge, no evidence 
suggests that treating depression reduces risk of 
developing dementia, and no identified interventions 
exist to prevent depression in the general population. 
The final two risk factors were low social contact and 
physical inactivity; evidence for both risk factors was 
insufficient for effective interventions to be modelled.33
Selected risk factors, prevalence of untreated factor at 
time of potential intervention, RR, and associated PAF 
are presented in table 1. The effects of each intervention 
and all interventions combined on QALYs, costs, and 
dementia prevalence are discussed here, and intervention 
costs are detailed in the appendix (pp 7–9).
The target group for treatment of hypertension are 
those in middle age (46–64 years) with untreated or 
uncontrolled hypertension. From national surveys, 
prevalence of untreated or uncontrolled hypertension in 
mid-life is 22% in England12 so the intervention was 
applied to this group. Costs vary with dose and variant of 
antihypertensives, but as of 2018, combination of three 
antihypertensives (angiotensin converting enzyme 
inhibitor, calcium channel blocker, and diuretic) costs 
£67 a year.12,15 Allowing for two consultations a year, total 
annual cost is £141.15 Discounted lifetime net cost per 
person treated is £376 and QALY gain is 0·039. Cost per 
QALY is £9550, which is substantially below the NICE 
threshold of £20 000 per QALY.34 Annual expenditure for 
this treatment for the whole middle-aged population in 
England with hypertension is £730 million, and dementia 
prevalence falls by 5%.
8% of older adults (65 years and older) currently smoke 
and this group is the target patient group for nicotine 
replacement therapy.34 This therapy to aid smoking 
cessation was assumed to be given at age 65 years. The 
comparator in the meta-analysis on which we rely 
includes other smoking cessation therapies.29 Because 
our target group would not otherwise receive any therapy 
at all, we use the cost of the intervention for which the 
participant receives nicotine replacement therapy in 
addition to support from a health professional. We use 
an 8-week period (£56 with nicotine gum at £1 a day).29 A 
typical upper limit of low support is 30 min with a GP 
(£114) plus two sessions of 30 min with a practice nurse 
(£52) per 8 weeks.29 The intervention both reduces costs 
and improves quality of life, dominating over the so-
called do-nothing option. Discounted cost saving per 
person treated is £1569 and QALY gain is 0·097. We 
carried out a threshold analysis of the intervention cost 
that would deliver a cost up to the NICE threshold of 
£20 000 per QALY: the cost could increase by 111% and 
remain below the NICE threshold. The annual cost of 
delivering the intervention is £12 million a year and the 
7% permanent quit rate eventually leads to a reduction of 
0·15% in dementia prevalence.
The prevalence of diabetes in people 65 years and older 
is 15%.11 The Finnish Diabetes Prevention Study35 
comprised an annual GP visit, at a cost of £34 each (when 
converted to UK currency), for 6 years. Consultations 
with a nutritionist (seven in year one, four in subsequent 
years) were assumed to last for 30 min, remunerated at 
band 5 professional scale.14 The duration and frequency 
of group therapy sessions were not specified in the paper; 
we assumed a cost of £76 per person per year. The total 
cost per participant in year one was £232, and 
£180 per year in subsequent years. We applied the 
findings to a cohort of overweight 65-year-olds with 
impaired glucose tolerance. We adopted a stopping rule 
of diagnosis with dementia or diabetes, or 6 years, 
whichever came first, because this was the trial duration 
and benefits were related to this treatment length. Cost 
per person treated increases by £504 and QALY gain is 
0·006. Cost per QALY (£86 000) is above the NICE 
threshold. The intervention would not be seen by NICE 
as cost-effective for its effect on dementia.
The lifestyle intervention was expensive because of the 
number of sessions with a professional; therefore, we 
carried out a sensitivity analysis using results from a trial 
of metformin to prevent diabetes. The Diabetes 
Prevention Research Group recruited adults (mean age 
51 (SD 10·7) at high risk of diabetes from impaired 
glucose tolerance and raised BMI, and randomly 
assigned them to metformin, placebo, or lifestyle 
intervention.36 The annual incidence of diabetes was 
5·1% with drug therapy and 6·1% without. Therapy was 
850 mg met formin, twice daily, at annual cost of £33.36 
We added one GP consultation per year (cost £34).15 The 
results of this sensitivity analysis showed an increase of 
£423 in lifetime cost per person treated and a QALY gain 
of 0·002. The cost per QALY (£189 000) is also above the 
NICE threshold.14
9% of middle-aged adults (age 45–64 years) have 
hearing loss at 3 kHz11 as measured by a pure-tone 
audiometry screening test. We used this cutoff as it is 
likely to encompass most age-related hearing loss and to 
represent those who would benefit from a hearing aid.11 
Of those with midlife hearing loss, 17% currently use a 
hearing aid, so we considered the effect of providing 
hearing aids to those with hearing loss who are not using 
an aid (8% of all middle-aged adults).37 The cost of 
supplying and fitting a hearing aid, including follow-up, 
is £370 and two adjustments annually cost £25 each,14 
Prevalence, p (%) Adjusted relative risk PAF (%)
With vs without 
the risk factor, r
With risk factor* 
r / (pr + 1 – p)
Without risk factor* 
1 / (pr + 1 – p)
Hypertension 22% 1·25 1·18 0·95 5%
Smoking 8% 1·27 1·24 0·98 2%
Diabetes 15% 1·15 1·13 0·98 2%
Hearing loss 8% 1·50 1·36 0·91 9%
Prevalence (p) of untreated risk factors at time of potential intervention are presented along with relative risks (r), 
and PAF adjusted for communality. PAF=population attributable fraction. *Relative to whole population.
Table 1: Prevalence of risk factors, adjusted relative risk, and PAF
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with hearing aids requiring replacement every 3 years. At 
age 45 years, discounted lifetime cost saving is £607 per 
person and QALY gain is 0·0798. Cost of therapy could 
be up to 68% higher without breaching the NICE 
threshold of £20 000 per QALY. Annual expenditure is 
£335 million and dementia prevalence eventually falls 
by 3·3%.
The effects of each and all interventions together on 
QALYs, costs, and dementia prevalence are substantial 
(tables 2 and 3). Considered together, treating hyper-
tension in midlife, stopping smoking, and providing 
hearing aids in later life are associated with QALY gains 
and lifetime savings per person. This translates into 
annual net savings in unpaid family care of £1051 million) 
and social care  of £866 million, resulting in total savings 
of £1863 million when NHS costs are considered. This is 
in addition to a dementia prevalence reduction of 8·5% 
(appendix pp 7–9).
The deterministic sensitivity analyses found that the 
leading influences on cost-effectiveness across all 
interventions were underlying incidence of dementia, 
excess risk of dementia for the risk factor, and 
intervention cost and effectiveness of the intervention 
(appendix pp 9–17). The cost of unpaid care in the mild 
stage of dementia is also prominent for all four 
interventions. If dementia incidence rates at the lower 
95% CI are applied, both antihypertensive therapy and 
hearing aids cease being cost-effective, but hearing aids 
only marginally so. Smoking cessation remains highly 
cost-effective but no longer dominates its com parator. 
Preventing diabetes remains not cost-effective even with 
incidence rates at upper 95% confidence limits. In a high 
proportion of probabilistic sensitivity analysis iterations, 
incremental cost-effectiveness is well below the NICE 
threshold of £20 000 for smoking cessation and hearing 
loss, indicating that smoking cessation has 0·03% 
probability of not being cost-effective at this threshold and 
treating hearing loss a 16·3% probability of not being cost-
effective. At the same £20 000 threshold, anti-hypertensive 
therapy has 85% probability of being cost-effective, and 
97% probability at the £30 000 threshold.
Discussion
To our knowledge, these are the first calculations of 
potential cost and cost-effectiveness of implementing 
evidence-based, feasible preventative interventions for 
dementia. Implementing three measures (treating 
hypertension, reducing smoking, providing hearing aids) 
improves health-related quality of life (as measured by 
QALYs), and reduces annual costs associated with 
dementia by £1·863 billion, accounting for intervention 
costs. These QALY gains and cost reductions come to 
fruition when the programme is fully operational and 
those treated in mid-life reach late life. Cost of the full 
intervention programme is £1·077 billion annually. 
Social care accounts for more savings than does health 
care. This estimate of cost savings is lower than 
previously suggested because previous studies omitted 
intervention costs. Therefore, our estimate is relatively 
conservative, but probably more accurate given our 
detailed calculations.
These interventions are cost-effective. Hearing aids 
and smoking cessation save money while improving 
quality of life, and are worth implementing for their 
effect on dementia alone. Additionally, there is huge 
potential benefit in stopping smoking and administering 
antihypertensives on cardio vascular health, and personal 
and other health benefits of hearing improvement. Our 
cost-effectiveness results are sensitive to perspective: if 
savings in unpaid care are excluded, interventions other 
than smoking cessation are not cost-effective by NICE 
criteria (appendix p 13). On the basis of the effect on 
dementia without considering effects on other illnesses, 
interventions to prevent diabetes by lifestyle changes or 
drug therapy are not cost-effective.
We assumed risk factors cause dementia, so addressing 
risk factors reduces dementia risk. Evidence from trials 
suggests that treating hypertension reduces cognitive 
Cost of therapy 
(millions of £) 
£m
Savings in NHS 
treatment 
(millions of £) £m
Savings in social 
care (millions of £) 
£m
Savings in informal 
care (millions of £) 
£m





Antihypertensive therapy 730 –42 497 614 1077 5·0%
Nicotine replacement therapy 12 –1 14 18 31 0·2%
Hearing aid 335 –28 355 423 755 3·3%
Total 1077 –71 866 1051 1863 8·5%
*Costs and savings are per year once the programme is mature, with all those treated in middle age having reached late old age, assuming all eligible are treated. †Net cost 
savings are a total of NHS treatment savings, social care savings, and savings in informal care, in addition to a small amount of other cost savings.
Table 3: Total annual costs and savings of chosen interventions*
Intervention QALY gain Cost saving (£) Cost per QALY (£)
Hypertension Antihypertensive therapy 0·0393 –376 9555
Smoking Nicotine replacement therapy 0·0967 1569 Dominates
Hearing loss at 3 kHz Hearing aid 0·0798 607 Dominates
Diabetes Prevention package 0·0060 –504 86 000
An intervention dominates when it results in better outcomes and lower costs. QALY=quality-adjusted life-year.
Table 2: Lifetime cost savings and benefit per person treated for each risk factor
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decline, but for the other risk factors, evidence is 
observational, although strong, consistent, biologically 
plausible, and dose-related.4 Causal links are therefore 
likely but not proven. We have assumed that interventions 
reduce but do not eliminate dementia risk.
There will not be full intervention uptake and 
effectiveness can differ in routine practice from trials. 
Some people who are hypertensive or with hearing loss 
or who smoke do not want interventions. Costs and 
benefits would decrease proportionately with decrease in 
uptake, but cost-effectiveness would not change because 
it is independent of uptake.
We have assumed that, if NICE guidelines are followed, 
controlling hypertension might be possible; however, 
this might not happen in practice. Some people will not 
agree to interventions, and others will not adhere to 
them, possibly because of treatment adverse effects. We 
have not modelled this, but we advocate established 
treatments using results from trials. We consider 
interventions in the whole population, not exploring 
differences by sex, or in early onset dementia.
Consequently, the interventions might prove less 
successful in practice than we assume, but there is 
considerable room for the interventions to absorb 
reductions in efficacy and remain cost-saving or cost-
effective. We did deterministic and probabilistic 
sensitivity analyses to understand how changes in model 
assumptions affect our conclusions. We accounted for 
risk factor communality and used conservative estimates. 
For hypertension, we costed for treatment with three 
antihypertensive drugs, which is often unnecessary. We 
assumed treatment at relatively young ages—for 
example, many people might not need hearing aids by 
age 45 years, and so treatment costs would be lower. We 
used a relatively high threshold for effects of hearing loss 
on cognition, for increased benefit. Not all the inter-
ventions were cost-effective, but our calculations 
emphasise the potential benefit to people with dementia, 
their families, and wider society.
These interventions would also be expected to reduce 
risk of cardiovascular disease and other diseases such as 
stroke, aside from dementia, but we did not model these, 
and therefore have underestimated the overall cost-saving 
effects. A delay of dementia until very old age might 
decrease morbidity: people could live for more years free 
of multiple illnesses. Nowadays, reductions in dementia 
have been in higher socioeconomic groups. Future 
interventions should also target other groups for greater 
equity of access and to increase overall benefit.
We have not included costs of promoting increased use 
of nicotine replacement therapy, hearing aids, or anti-
hypertensives. We started our analysis when people decide 
on screening for risk factor or start treatment for them.
Our calculations are based on costs in England but our 
methods are generalisable to other countries. We expect 
these interventions will be valuable in similar settings. In 
low-income and middle-income countries with a greater 
PAF from hypertension, hearing loss, and smoking, they 
might be even more useful than we hope they will be in 
the UK.
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